Nightstar Therapeutics Company
Nightstar is biopharmaceutical company, focused on developing gene therapies for retinal dystrophies.
Headquarters:
London, England, United Kingdom
Number Of Exists:
Post-IPO Equity
Total Funding:
$174.6M
Founded Date:
2013
Employee Number:
11-50
Investment Stage:
N/A
Last Funding Type:
Post-IPO Equity
Investor Type:
Company
Investors Number:
4
Technology:
Neurological Disorders
Funding Status:
M&A
Estimated Revenue:
$1M to $10M
Industry:
Gene Therapy